Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells

BACKGROUND: Chimeric antigen receptor (CAR) T cells engineered to recognize and target tumor associated antigens have made a profound impact on the quality of life for many patients with cancer. However, tumor heterogeneity and intratumoral immune suppression reduce the efficacy of this approach, al...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yi-Chiu, Kuo, Cheng-Fu, Jenkins, Kurt, Hung, Alfur Fu-Hsin, Chang, Wen-Chung, Park, Miso, Aguilar, Brenda, Starr, Renate, Hibbard, Jonathan, Brown, Christine, Williams, John C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214433/
https://www.ncbi.nlm.nih.gov/pubmed/35728874
http://dx.doi.org/10.1136/jitc-2021-003752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214433/
https://www.ncbi.nlm.nih.gov/pubmed/35728874
http://dx.doi.org/10.1136/jitc-2021-003752

Ejemplares similares